Selling, General, and Administrative Costs: United Therapeutics Corporation vs MorphoSys AG

A Comparative Analysis of SG&A Expenses: United Therapeutics vs. MorphoSys AG

In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of United Therapeutics Corporation and MorphoSys AG from 2014 to 2023. Over this period, United Therapeutics consistently outspent MorphoSys AG, with its SG&A expenses peaking at approximately $487 million in 2022, a 28% increase from 2014. In contrast, MorphoSys AG's expenses saw a dramatic rise, particularly between 2019 and 2021, where they surged by over 200%, reaching nearly $200 million in 2021. This stark contrast highlights differing strategic priorities, with United Therapeutics maintaining steady growth, while MorphoSys AG experienced more volatile financial management. Such insights are invaluable for investors and industry analysts seeking to understand the financial health and strategic direction of these pharmaceutical giants.